References
- Lichtenstein GR, Hanauer SB, Sandborn WJ. The practice committee of the American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;(April 2008):1–19. DOI:10.1038/ajg.2008.168
- Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–1207. DOI:10.1016/j.crohns.2014.04.005
- Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease : current management. J Crohn’s Colitis. 2010;4(1):28–62. DOI:10.1016/j.crohns.2009.12.002
- Lim WC, Wang Y, MacDonald JK, et al. Aminosalicylates for induction of remission or response in Crohn’s disease (Review). Cochrane Database of Systematic Reviews 2016, Issue 7. Art. No.: CD008870. DOI: 10.1002/14651858.CD008870.pub2.
- Levine JS, Burakoff R. Inflammatory bowel disease: medical considerations. In: Greenberger NJ, Blumberg RS, Burakoff R, editors. Current diagnosis & treatment gastroenterology, hepatology, & endoscopy. 3rd ed. New York: McGraw-Hill Education; 2016. p. 26–39.
- Me K, Rezaie A, Ch S, et al. Budesonide for maintenance of remission in Crohn ’ s disease (Review). Cochrane Libr. 2014;(8):10–13. DOI:10.1002/14651858.CD002913.pub2
- Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13(9):R79. DOI:10.1186/gb-2012-13-9-r79
- Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science (80-). 2011;334(6052):105–109. DOI:10.1126/science.1208344
- Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2016. DOI:10.1007/s00535-016-1283-0
- Burakoff R, Pabby V, Onyewadume L, et al. Blood-based biomarkers used to predict disease activity in Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2015;21(5):1132–1140. DOI:10.1097/MIB.0000000000000340
- Colombel JJF, Sandborn WWJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease (SONIC study). N Engl J Med. 2010;362:1383–1395. DOI:10.1056/NEJMoa0904492
- Jones JL, Kaplan GG, Peyrin-Biroulet L, et al. Systematic reviews and meta-analyses effects of concomitant immunomodulator therapy on efficacy and safety of anti–tumor necrosis factor therapy for Crohn’s disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2015;13(13):2233–2240.e2. DOI:10.1016/j.cgh.2015.06.034
- Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysis. Gastroenterology. 2015;148(2):344–354. DOI:10.1053/j.gastro.2014.10.011
- Barnes EL, Alison G, Winter RW, et al. Sequential combination therapy versus monotherapy: a lack of benefit in time to inflammatory bowel disease related surgery. Dig Dis Sci. 2016;61:3261–3269.
- Melmed GY, Spiegel BM, Bressler B, et al. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn’s disease: one size does not fit all. Clin Gastroenterol Hepatol. 2010;8(8):655–659. DOI:10.1016/j.cgh.2010.04.023
- Louis E, Mary J-Y, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab is stopped. Gastroenterology. 2012;142(1):63–70.e5. DOI:10.1053/j.gastro.2011.09.034
- Schwartz DA, Ghazi LJ, Regueiro M, et al. Guidelines for the multidisciplinary management of Crohn’s perianal fistulas: summary statement. Inflamm Bowel Dis. 2015;21(4):723–730. DOI:10.1097/MIB.0000000000000315